MedTrace Logo

Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers

NCT01638598 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-11-01

No results posted yet for this study

Summary

Safety,tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1021958 after single rising doses (SRD) in healthy Asian male volunteers

Conditions

  • Healthy

Interventions

DRUG

matching placebo

matching placebo in each dose level

DRUG

Test drug

BI 1021958

DRUG

matching placebo

matching placebo in each dose level

DRUG

Test drug

BI 1021958

DRUG

Test drug

BI 1021958

DRUG

Test drug

BI 1021958

DRUG

Test drug

BI 1021958

DRUG

matching placebo

matching placebo in each dose level

DRUG

matching placebo

matching placebo in each dose level

DRUG

matching placebo

matching placebo in each dose level

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01638598 on ClinicalTrials.gov